Answers are grounded in this paper and cite their sources.
Historically marginalized communities are disproportionately affected by cardiometabolic diseases yet are underrepresented in clinical trials that investigate needed interventions. This review investigates the barriers to equitable inclusion in clinical trials, identifying opportunities for improvement at the institutional, trial, community, and individual level. It proposes a social determinants-based approach that serves as a toolkit to target these barriers using structural, economic, community, healthcare access, and technology solutions, supporting constructive improvement in the clinical trial recruitment process.
No takes yet. Share an insight, caveat, or question.
King et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: